At the time of writing, Pliant Therapeutics Inc [PLRX] stock is trading at $13.88, up 3.81%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PLRX shares have gain 10.77% over the last week, with a monthly amount glided 30.21%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pliant Therapeutics Inc [NASDAQ: PLRX] stock has seen the most recent analyst activity on December 08, 2023, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $41. Previously, Canaccord Genuity started tracking the stock with Buy rating on May 18, 2023, and set its price target to $48. On April 13, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $44 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $33 on December 14, 2022. JP Morgan initiated its recommendation with a Overweight and recommended $42 as its price target on December 07, 2022. Citigroup started tracking with a Buy rating for this stock on September 01, 2022, and assigned it a price target of $36. In a note dated July 20, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $33 on this stock.
For the past year, the stock price of Pliant Therapeutics Inc fluctuated between $10.29 and $20.23. Currently, Wall Street analysts expect the stock to reach $40.5 within the next 12 months. Pliant Therapeutics Inc [NASDAQ: PLRX] shares were valued at $13.88 at the most recent close of the market. An investor can expect a potential return of 191.79% based on the average PLRX price forecast.
Analyzing the PLRX fundamentals
According to Pliant Therapeutics Inc [NASDAQ:PLRX], the company’s sales were 0.25M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -38.22%, Pretax Profit Margin comes in at -33.56%, and Net Profit Margin reading is -33.56%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.35 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.36 points at the first support level, and at 12.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.27, and for the 2nd resistance point, it is at 14.67.
Ratios To Look Out For
It is important to note that Pliant Therapeutics Inc [NASDAQ:PLRX] has a current ratio of 16.12. In addition, the Quick Ratio stands at 16.12 and the Cash Ratio stands at 3.76. Considering the valuation of this stock, the price to sales ratio is 3349.52, the price to book ratio is 1.91.
Transactions by insiders
Recent insider trading involved Coulie Bernard, President and CEO, that happened on Jul 10 ’24 when 38710.0 shares were sold. Chief Medical Officer, Lefebvre Eric completed a deal on Jul 10 ’24 to sell 12319.0 shares. Meanwhile, Chief Financial Officer Cummings Keith Lamont sold 10911.0 shares on Jul 10 ’24.
